Online citations, reference lists, and bibliographies.
← Back to Search

Malignant Pleural Mesothelioma: New Hope In The Horizon With Novel Therapeutic Strategies.

J. Remon, N. Reguart, J. Corral, P. Lianes
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is a rare but aggressive malignancy of the pleura, with a strong causal link to asbestos exposure. MPM incidence has been increasing in recent years and it is not expected to fall off in the next two decades. Prognosis of MPM patients is modest since the vast majority of patients are diagnosed at advanced stage and because platinum-based chemotherapy remains the cornerstone of treatment, with no standard second line treatment. Most current efforts to improve outcomes are based on a better understanding of the stromal compartment and deregulated pathways leading ultimately to the design of clinical trials based on novel therapeutic approaches such as immunotherapy or molecular-directed compounds. This review seeks to update the last clinical trials investigating novel agents in unresectable MPM.
This paper references
10.1289/ehp.1002845
Global Magnitude of Reported and Unreported Mesothelioma
Eun-Kee Park (2011)
hTNF as second - line treatment in malignant pleural mesothelioma ( MPM )
G Rossoni (2012)
10.1016/j.lungcan.2013.11.011
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
P. Zucali (2014)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1200/jco.2013.31.18_suppl.cra8007
A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).
G. Goss (2013)
10.1093/annonc/mdu098
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.
F. Barlesi (2014)
Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.
J. Zhang (2012)
10.1016/S1556-0864(15)30351-8
Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program
P. Jänne (2006)
10.1200/jco.2012.30.15_suppl.7083
SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM).
L. Garland (2012)
10.1038/ncponc1039
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
10.1158/1078-0432.CCR-11-2375
New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment
M. Ladanyi (2012)
10.1200/JCO.2014.32.4_SUPPL.52
Characterization of immune-related adverse events (irAEs) in a phase 3 trial of ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel mCRPC.
T. Beer (2014)
10.1158/1078-0432.CCR-11-0946
Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
S. Landreville (2011)
10.1200/JCO.2014.32.15_SUPPL.7507
Randomized trial of arginine deprivation with pegylated arginine deiminase in patients with malignant pleural mesothelioma.
P. Szlosarek (2014)
10.1200/JCO.2012.47.1102
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
L. Paz-Ares (2013)
10.1016/j.lungcan.2010.12.004
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
10.1038/mt.2010.159
Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.
Z. Fridlender (2010)
Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer additional analysis from clinical study of the engineered antibody MPDL3280A (anti-PDL1)
J Soria (2013)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1016/j.lungcan.2012.05.111
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
J. Dowell (2012)
10.1172/JCI34739
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.
A. Carracedo (2008)
10.4161/onci.26218
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients
J. Stevenson (2013)
10.1007/s00280-014-2429-5
A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma
O. Arrieta (2014)
10.1002/cncr.28875
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125
R. Hassan (2014)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
10.1200/JCO.2014.32.15_SUPPL.7589
T-cell inflamed phenotype and PDL1 expression in malignant mesothelioma.
H. Kindler (2014)
10.1016/j.lungcan.2012.06.011
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
N. Campbell (2012)
10.1016/j.lungcan.2014.05.006
Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.
J. Raphael (2014)
10.1016/j.lungcan.2011.08.011
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
10.2471/BLT.11.086678
Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008.
V. Delgermaa (2011)
Efficacy of phase I trials in malignant pleural mesothelioma : description of a series of patients in a single institution
J Raphael (2014)
10.1038/sj.onc.1209587
Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK
P. Poulikakos (2006)
10.1038/sj.bjc.6604442
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
Exposure-response relationship of amatuximab in combination with pemetrexed and cisplatin in patients with unresectable pleural mesotelioma
JD Maltzman (2013)
GLOBAL PATTERNS IN THE INCIDENCE OF MALIGNANT MESOTHELIOMA, 1988-2002, USING DATA PUBLISHED BY THE INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (IARC)
Matthew Soeberg (2013)
Efficacy of phase I trials in malignant pleural mesothelioma: description of a series of patients in a single institution. Lung Cancer 2014;85:251–7
J Raphael (2014)
10.1200/JCO.2012.30.15_SUPPL.7076
NGR-hTNF as second-line treatment in malignant pleural mesothelioma (MPM).
G. Rossoni (2012)
10.1186/s12885-015-1519-z
The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma
G. Ak (2015)
10.1016/S1470-2045(13)70125-6
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
W. Buikhuisen (2013)
10.1200/JCO.2014.32.15_SUPPL.7532
Antimesothelin vaccine CRS-207 plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM).
R. Hassan (2014)
10.1097/COC.0000000000000059
Emerging Immunotherapies in the Treatment of Non–small Cell Lung Cancer (NSCLC): The Role of Immune Checkpoint Inhibitors
C. Langer (2015)
10.1007/978-3-642-10862-4_2
Epidemiology of mesothelioma and historical background.
J. Craighead (2011)
Phase II study of intermitent sunitinib maleate as second-line therapy in progressive in malignant pleural mesotelioma
AK Nowak (2012)
10.1002/path.3979
BRCA1 is an essential mediator of vinorelbine‐induced apoptosis in mesothelioma
S. Busacca (2012)
10.1038/sj.bjc.6600505
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
10.1016/S1470-2045(13)70586-2
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
M. Reck (2014)
10.1097/JTO.0000000000000177
B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
A. Mansfield (2014)
10.1097/JTO.0b013e3182333df5
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
S. Laurie (2011)
Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in patients with advanced solid tumors
JC Soria (2012)
10.1183/09031936.06.00135305
Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses
J. Hegmans (2006)
10.1126/scitranslmed.3006941
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
R. Hassan (2013)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1093/ANNONC/MDI187
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
C. Manegold (2005)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012;75:360–7
PA Zucali (2012)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1200/JCO.2012.30.15_SUPPL.7030
Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: Results of a multicenter phase II clinical trial.
R. Hassan (2012)
10.1038/bjc.2014.220
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
S. Zhou (2014)
10.1158/1078-0432.CCR-10-2275
Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
R. Hassan (2010)
10.3978/j.issn.2225-319X.2012.11.04
Malignant pleural mesothelioma: an epidemiological perspective.
Benjamin M. Robinson (2012)
Status of Anaplastic Lymphoma Kinase (ALK) in malignant mesothelioma.
Serena Varesano (2014)
10.1158/1078-0432.CCR-06-1101
In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion
P. Szlosarek (2006)
10.1053/j.seminoncol.2013.12.014
Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?
J. Brahmer (2014)
10.1097/JTO.0b013e31829e7ef9
Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations
M. Zauderer (2013)
SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM).
Linda L. Garland (2012)
10.1016/j.lungcan.2013.05.006
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
A. Nowak (2013)
10.1158/1078-0432.CCR-11-2614
Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients
E. Servais (2012)
10.1016/S0959-8049(11)70098-3
VANTAGE 014: Vorinostat (V) in Patients With Advanced Malignant Pleural Mesothelioma (MPM) who Have Failed Prior Pemetrexed and Either Cisplatin or Carboplatin Therapy: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial
L. Krug (2011)
10.1200/JCO.2014.32.15_SUPPL.7530
Next-generation sequencing in malignant pleural mesothelioma: A retrospective study.
G. Scagliotti (2014)
10.1097/JTO.0b013e31825f22ee
A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma
A. Nowak (2012)
10.1146/annurev-publhealth-031811-124704
The worldwide pandemic of asbestos-related diseases.
L. Stayner (2013)
10.1016/j.athoracsur.2014.04.040
Women with malignant pleural mesothelioma have a threefold better survival rate than men.
E. Taioli (2014)
10.1200/JCO.2014.32.15_SUPPL.7531
A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients.
L. Calabrò (2014)
10.1007/s12253-013-9677-2
BAP1 Protein is a Progression Factor in Malignant Pleural Mesothelioma
L. Arzt (2013)
10.1097/JTO.0b013e3181839693
Inhibition of Hsp90 Leads to Cell Cycle Arrest and Apoptosis in Human Malignant Pleural Mesothelioma
J. Okamoto (2008)
10.1126/scitranslmed.3008639
Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship
I. Shapiro (2014)
10.1016/j.lungcan.2008.09.008
Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
C. Lee (2009)
Biomarker results from a phase I study of cediranib in combination with cisplatin and pemetrexed in chemonaïve patients with malignant pleural mesothelioma (SWOG 0905)
J Fujmoto (2013)
10.1097/CEJ.0b013e32834dbc56
Role of stopping exposure and recent exposure to asbestos in the risk of mesothelioma
C. la Vecchia (2012)
10.1093/ANNONC/MDU438.66
1556O_PRANALYSIS OF EXPRESSION OF PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) IN MALIGNANT PLEURAL MESOTHELIOMA (MPM)
S. Cedrés (2014)
10.1097/JTO.0b013e318229586e
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509
L. Garland (2011)
10.1038/bjc.2013.368
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. Ceresoli (2013)
10.1097/JTO.0b013e31828c2b26
Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
S. Papa (2013)
10.1016/S1556-0864(15)31509-4
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
D. P. M. van den Bogaert (2006)
Evaluation of tolerability and anti-tumor activity of GDC0980, an oral PI3K/mTOR inhibitor, administrated to patients with advanced malignant pleural mesothelioma
S Dolly (2013)
10.1200/JCO.2010.28.15_SUPPL.7020
IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma.
G. Zalcman (2010)
10.1371/journal.pone.0121071
Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
S. Cedrés (2015)
10.1200/JCO.2012.30.15_SUPPL.3000
Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.
J. Soria (2012)
10.1097/JTO.0b013e31817c73ec
Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program
Paul Taylor (2008)
10.3816/CLC.2010.n.005
Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
N. Katirtzoglou (2010)
10.1186/2051-1426-3-S2-P161
Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)
R. Hassan (2015)
10.1158/0008-5472.CAN-14-1328
Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.
Jinfei Xu (2014)



This paper is referenced by
10.3892/ol.2018.9761
Diagnosis of mesothelioma with deep learning
X. Hu (2019)
10.1080/03007995.2016.1226165
Symptom burden in mesothelioma patients admitted to home palliative care
S. Mercadante (2016)
10.1007/s00262-016-1844-3
CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor
S. Roncella (2016)
10.1515/pp-2016-0013
Chemosensitivity and resistance testing in malignant effusions with focus on primary malignant mesothelioma and metastatic adenocarcinoma
Adam Szulkin (2016)
10.2147/CBF.S72199
MicroRNAs as potential biomarkers in malignant pleural mesothelioma
E. Santoni-Rugiu (2015)
10.2174/1573394713666170907160734
Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target
B. Doonan (2017)
10.1016/J.RMCLC.2015.06.010
ENFERMEDADES RESPIRATORIAS OCUPACIONALES
F. M. Salinas (2015)
10.2147/OTT.S134126
Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma
K. Aigner (2017)
La réponse antitumorale des macrophages dirigée contre les cellules de mésothéliome pleural malin
Clotilde Hoyos (2017)
10.21037/tlcr.2017.06.01
Novel systemic therapy against malignant pleural mesothelioma.
M. R. Mancuso (2017)
10.1177/2036361319863498
Costs of medical care for mesothelioma
E. Borrelli (2019)
10.18632/oncotarget.24644
MiR-21 over-expression and Programmed Cell Death 4 down-regulation features malignant pleural mesothelioma
L. Nicolè (2018)
High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.
Z. G. Zimling (2015)
10.1186/s12940-018-0439-1
Mortality among workers exposed to asbestos at the shipyard of Genoa, Italy: a 55 years follow-up
D. Merlo (2018)
10.1080/21678707.2017.1325358
Current and prospective pharmacotherapies for the treatment of pleural mesothelioma
Emyr Bakker (2017)
10.1007/S00761-014-2886-9
Pleuramesotheliome: Multimodales Management als klinische Herausforderung
Rudolf A. Hatz (2015)
10.1080/2162402X.2017.1398874
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment
C. Riganti (2018)
10.1016/j.cllc.2020.05.020
Clinical Features in Patients With Malignant Pleural Mesothelioma With 5-Year Survival and Evaluation of Original Diagnoses.
Juuso Paajanen (2020)
10.1158/1078-0432.CCR-17-1345
Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses
L. Schunselaar (2017)
Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma.
G. Ugurluer (2016)
10.1007/s00508-016-1036-3
Management of malignant pleural mesothelioma—part 2: therapeutic approaches
M. A. Hoda (2016)
10.2217/fon-2017-0224
Advances in systemic therapy for malignant mesothelioma: future perspectives.
N. Sobhani (2017)
10.1097/MD.0000000000003351
Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma
Xu-quan Jing (2016)
10.1186/s12931-017-0546-5
CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives
L. Cortes-Dericks (2017)
10.1002/ijc.32419
Wnt/IL‐1β/IL‐8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5
Vladan Milošević (2019)
Investigating methods regarding diagnostic and prognostic biomarkers for malignant mesothelioma
H. Matsuzaki (2015)
10.1016/j.jtho.2018.06.008
Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates
L. Schunselaar (2018)
10.1016/j.jtho.2019.03.029
Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma.
I. C. Salaroglio (2019)
10.2147/IJN.S186344
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
E. Cova (2019)
10.1517/14712598.2015.1116515
Tremelimumab for the treatment of malignant mesothelioma
A. Guazzelli (2015)
10.1016/j.critrevonc.2016.08.011
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
G. Bronte (2016)
10.1016/j.lungcan.2018.03.022
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
J. Kopecka (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar